Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) and Gowan Company LLC today announced a new partnership using Starpharma’s Priostar^® dendrimer technology in crop protection formulations.

Under the agreement, Starpharma’s Priostar^® dendrimers will be evaluated as potential enhancements for certain Gowan products intended for high value markets.

Melbourne, Australia: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had achieved improved tumour-inhibiting efficacy and reduced overall toxicity using a dendrimer enhanced version of the blockbuster cancer drug, oxaliplatin (ELOXATIN®).

These positive results were demonstrated in a pre-clinical study, which examined dendrimer-enhanced nanoparticle versions of oxaliplatin compared with ELOXATIN® (oxaliplatin) in a colon cancer model (xenograft).

Herald Sun business journalist John Beveridge reported on the versatility of Starpharma’s dendrimer technology.

"There is no secret why Starpharma is going after docetaxel given its sales of $US2.14 billion in 2009, but there is a long list of other potential drugs that could benefit from improved delivery mechanisms. The other thing I like about Starpharma is that it has lots of irons in the fire. Its phase-three Vivagel trials for relieving symptoms of bacterial vaginosis have potential to recover ground lost when trials as a cure for that disease marginally failed to reach their endpoint. Plus the potential for removing solvents and greatly improving the efficacy of a broad range of agricultural chemicals is a much-underestimated source of future profits for Starpharma."

Go to the article (external link)